Qiagen, Maverix Expand Co-marketing Agreement | GenomeWeb

NEW YORK (GenomeWeb News) – Maverix Biomics said this week that it has extended an existing co-marketing agreement with Qiagen by integrating a second set of software products to support customers analyzing data from RNA-sequencing studies.

The partners have combined Qiagen's Ingenuity Pathway Analysis software with the Maverix Analytic platform to simplify the analysis and interpretation of RNA-seq data as well as speed up research, Maverix said. Last November, the companies integrated Qiagen Ingenuity iReport with the Maverix platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

Feb
25
Sponsored by
Omicia

This webinar will demonstrate how ACMG's recommended variant scoring and classification rules may be applied to standardize reporting on sequencing test results within and across institutions.